Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma scintigraphy study comparing pulmonary deposition and pharmacokinetics of albuterol inhalation solution via eFlow nebuliser versus salbutamol nebuliser solution via LC Plus nebuliser in asthmatic patients
2007-000267-17Phase 2Terminated
- Sponsor
- Verus Pharmaceuticals
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of salbutamol in asthma and bronchopulmonary diseases (2 arms), sponsored by Verus Pharmaceuticals. Primary endpoint: Pulmonary deposition of radiolabelled salbutamol. Started Jan 2007; status: terminated.
02
Drugs
salbutamol
03
Conditions
asthmabronchopulmonary diseases
Beyond the preview
Go deeper on 2007-000267-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000267-17.